A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial by Dennis, M, Burnett, A, Hills, R, Thomas, I, Ariti, C, Severinsen, MT, Hemmaway, C, Greaves, P, Clark, RE, Copland, M, Russell, N, National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working Group